395 research outputs found
Canine sound production, perception, and processing
No full textThe first part of the chapter explains the mechanisms underly- ing the production of canine vocalizations with particular ref- erence to the structures mainly involved in the emission of the different sounds. Spectrographic analyses of the most common dog vocalizations are also presented. Hypotheses about the neuroendocrine control of canine vocalizations result directly from studies that analyze the relationships between hormones and behavior with particular reference to vasopressin and vo- calizations emitted during competitive behaviors. The second part of the chapter deals with canine brain auditory pathways involved in vocal perception with particular reference to the different specializations of dogs and human brain areas in pro- cessing distinct types of auditory signals. Finally, effects of vo- calizations on behavior and development are discussed
Vibration and Noise Exposure during Pre-Commercial Thinning Operations: What Are the Ergonomic Benefits of the Latest Generation Professional-Grade Battery-Powered Chainsaws?
No full textIn order to compare the vibration and noise exposure of STIHL’s battery-powered MSA 220 C and the combustion driven MS 201 C, a professional operator was monitored during a pre-commercial thinning operation in a twenty-year-old hardwood stand. The vibration levels were measured with a tri-axial accelerometer on the front and rear handle of both the chainsaws, and assigned to five different work elements using a video documentation. Additionally, noise levels were recorded in one-minute intervals, with a dosemeter worn by the operator. The results show that battery-powered chainsaws, when compared to combustion-driven chainsaws, can reduce the daily vibration exposure by more than 45% and the noise dose by about 78.4%, during pre-commercial thinning tasks. Replacing combustion-driven chainsaws with battery-powered ones is therefore generally recommended, to reduce occupational health risks for operators, in this respect. However, the daily vibration exposure of about 2.42 m/s2, caused by the battery-powered chainsaw on the front handle, is still very close to the daily exposure action value set by the EU directives for health and safety requirements. The daily noise exposure of 89.18 dB(A) even exceeds the upper exposure action value. Consequently, a further reduction in the vibration exposure during work is desirable. With respect to noise exposure, additional measures must be implemented for conformity with the current safety standards, making the use of hearing protectors mandatory for electric chainsaws, too
Léon-François Hoffmann, Frauke Gewecke et Ulrich Fleichmann (dir.), Haïti 1804. Lumières et ténèbres. Impact et résonances d’une révolution
No full textNous avons avec ce volume des approches pluri-disciplinaires de la Révolution haïtienne ; mises au point historique, analyses littéraires, échos mémoriels. Il y a beaucoup de convergences entre le fait historique et l’histoire littéraire. La problématique centrale reste toutefois : comment utiliser des témoignages littéraires en histoire coloniale ? Mais, plus largement, ces contributions nous interrogent sur la nature même de la révolution de Saint-Domingue. Léon-François Hoffmann, qui est l..
Pre-clinical screening of novel two-photon photopolymerized biomaterials for bone implantation.
No full textAuthor Commentary: Mobile Music Technology: From Innovation to Ubiquitous Use
No full textThis author commentary chapter accompanies the re-publication of my co-authored 2006 paper ‘Mobile Music Technology: Report on an Emerging Community’ - one of 30 papers selected from 1,200 NIME papers to be included in the book ‘A NIME Reader: Fifteen Years of New Interfaces for Musical Expression, published by Springer and edited by Alexander Refsum Jensenius and Michael J. Lyons
Author Correction: A shared neural basis underlying psychiatric comorbidity
No full textCorrection to: Nature Medicine. Published online 24 April 2023. In the version of this article initially published, the STRATIFY data also included cohort data from the ESTRA consortium, though this was not acknowledged in the author list and the section in Methods on the Stratify dataset. The Methods are now updated, and the author list is amended to combine the STRATIFY and ESTRA consortium names and to include the following authors: Marina Bobou, M. John Broulidakis, Betteke Maria van Noort, Zuo Zhang, Lauren Robinson, Nilakshi Vaidya, Jeanne Winterer, Yuning Zhang, Sinead King, Hervé Lemaître, Ulrike Schmidt, Julia Sinclair, Argyris Stringaris and Sylvane Desrivières. The STRATIFY and ESTRA consortia are now combined to list Marina Bobou, M. John Broulidakis, Betteke Maria van Noort, Zuo Zhang, Lauren Robinson, Nilakshi Vaidya, Jeanne Winterer, Yuning Zhang, Sinead King, Gareth J. Barker, Arun L. W. Bokde, Hervé Lemaître, Frauke Nees, Dimitri Papadopoulos Orfanos, Ulrike Schmidt, Julia Sinclair, Argyris Stringaris, Henrik Walter, Robert Whelan, Sylvane Desrivières and Gunter Schumann as members, and the IMAGEN consortium is updated to also include Sylvane Desrivières. Affiliations, author contributions and acknowledgements have been updated to reflect the new authorship, and all changes have been made in the HTML and PDF versions of the article
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
No full textThe article ‘EGFR/Ras-induced CCL20 production modulates the tumour microenvironment’, written by Andreas Hippe, Stephan Alexander Braun, Péter Oláh, Peter Arne Gerber, Anne Schorr, Stephan Seeliger, Stephanie Holtz, Katharina Jannasch, Andor Pivarcsi, Bettina Buhren, Holger Schrumpf, Andreas Kislat, Erich Bünemann, Martin Steinhoff, Jens Fischer, Sérgio A. Lira, Petra Boukamp, Peter Hevezi, Nikolas Hendrik Stoecklein, Thomas Hoffmann, Frauke Alves, Jonathan Sleeman, Thomas Bauer, Jörg Klufa, Nicole Amberg, Maria Sibilia, Albert Zlotnik, Anja Müller- Homey and Bernhard Homey, was originally published electronically on the publisher’s internet portal on 30 June 2020 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 16 September 2021 to © The Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ licenses/by/4.0/. Open Access funding enabled and organized by Projekt DEAL
Author Correction: A shared neural basis underlying psychiatric comorbidity
No full textCorrection to: Nature Medicine https://doi.org/10.1038/s41591-023-02317-4. Published online 24 April 2023. In the version of this article initially published, the STRATIFY data also included cohort data from the ESTRA consortium, though this was not acknowledged in the author list and the section in Methods on the Stratify dataset. The Methods are now updated, and the author list is amended to combine the STRATIFY and ESTRA consortium names and to include the following authors: Marina Bobou, M. John Broulidakis, Betteke Maria van Noort, Zuo Zhang, Lauren Robinson, Nilakshi Vaidya, Jeanne Winterer, Yuning Zhang, Sinead King, Hervé Lemaître, Ulrike Schmidt, Julia Sinclair, Argyris Stringaris and Sylvane Desrivières. The STRATIFY and ESTRA consortia are now combined to list Marina Bobou, M. John Broulidakis, Betteke Maria van Noort, Zuo Zhang, Lauren Robinson, Nilakshi Vaidya, Jeanne Winterer, Yuning Zhang, Sinead King, Gareth J. Barker, Arun L. W. Bokde, Hervé Lemaître, Frauke Nees, Dimitri Papadopoulos Orfanos, Ulrike Schmidt, Julia Sinclair, Argyris Stringaris, Henrik Walter, Robert Whelan, Sylvane Desrivières and Gunter Schumann as members, and the IMAGEN consortium is updated to also include Sylvane Desrivières. Affiliations, author contributions and acknowledgements have been updated to reflect the new authorship, and all changes have been made in the HTML and PDF versions of the article.</p
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis
No full textBackground Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients. However, the current landscape is hindered by a paucity of comparative data that is crucial for treatment decisions. Objective This study aims to compare the effectiveness and safety of C5IT and FcRn antagonists in a real-world setting. Methods A retrospective analysis of 153 MG patients from 8 German specialised MG centres receiving either C5IT (26 eculizumab, 80 ravulizumab) or efgartigimod (47 patients) was conducted. Propensity score matching (PSM) was employed to compare changes in MG-specific outcome parameters within the first 6 months after treatment initiation, along with safety profiles and concomitant MG therapy. Results Both treatment strategies led to rapid clinical improvements and substantial reductions in prednisolone doses. However, insufficient response was noted in 20%–49.1% of patients based on Quantitative MG and MG Activities of Daily Living (MG-ADL) scores. We did not identify any new safety concerns. After PSM, 40 patients remained in each group. In both cohorts, reductions in MG-ADL as prespecified primary study endpoint were comparable. Moreover, analyses of secondary outcome parameters demonstrated similar results for C5IT versus FcRn. Conclusion In contrast to current meta-analyses and indirect comparisons of clinical trial data, our real-world study demonstrates comparable efficacy and safety of C5IT and FcRn antagonism in MG
- …
